Paul Bisaro
CIK 1237253 · Executive Chairman · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.77M
Companies
11
Total Filings
133
Lifetime Open-Market Net
-$38.45M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MYGN | Director | 157,142 | $3.26 | $512.3K | $27.6K | 6 | 2026-06-05 |
| ZTS | Director | 27,862 | $72.66 | $2.02M | $151.8K | 24 | 2026-05-13 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 71,131 | $0.34 | $24.2K | $42.3K | 5 | 2023-06-29 |
| TXMD | Director | 5,922 | $2.07 | $12.3K | $96.5K | 7 | 2022-10-03 |
| AMRX | Executive Chairman | 29,454 | $18.14 | $534.3K | $203.5K | 4 | 2019-05-09 |
| Allergan plc (AGN) Delisted | Director | 383,729 | — | — | -$16.97M | 13 | 2018-05-04 |
| ZBH | Director | — | $96.55 | — | $0 | 15 | 2017-04-04 |
| Impax Laboratories, LLC (IPXL) Delisted | President and CEO | — | — | — | $0 | 1 | 2017-03-29 |
| ACT | Exec Chairman | 422,531 | $48.96 | $20.69M | $0 | 2 | 2015-03-09 |
| Actavis, Inc. (WPI) Delisted | President & CEO | 307,339 | — | — | $0 | 12 | 2012-03-16 |
| BARR PHARMACEUTICALS INC (BRL) Delisted | 133,078 | — | — | -$22.00M | 25 | 2007-10-24 |
Recent Filings · Page 11 of 14
133 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-03-08 | Actavis, Inc. (WPI) Delisted | Tax (F) | −11,933 | -$677.7K | EDGAR |
| 2011-03-04 | Actavis, Inc. (WPI) Delisted | Grant (A) | +67,710 | $0 | EDGAR |
| 2010-03-16 | Actavis, Inc. (WPI) Delisted | Tax (F) | −5,978 | -$247.3K | EDGAR |
| 2010-02-26 | Actavis, Inc. (WPI) Delisted | Grant (A) | +81,181 | $0 | EDGAR |
| 2009-09-08 | Actavis, Inc. (WPI) Delisted | Tax (F) | −6,911 | -$240.6K | EDGAR |
| 2009-03-06 | Actavis, Inc. (WPI) Delisted | Grant (A) | +73,553 | $0 | EDGAR |
| 2008-03-14 | Actavis, Inc. (WPI) Delisted | Grant (A) | +36,850 | $0 | EDGAR |
| 2007-10-24 | BARR PHARMACEUTICALS INC (BRL) Delisted | Mixed | — | -$869.6K | EDGAR |
| 2007-10-22 | BARR PHARMACEUTICALS INC (BRL) Delisted | Mixed | — | -$277.0K | EDGAR |
| 2007-10-19 | BARR PHARMACEUTICALS INC (BRL) Delisted | Mixed | — | -$281.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.